Comparative trial between an ultra-short and long protocol of luteinizing hormone-releasing hormone agonist for ovarian stimulation in in-vitro fertilization.

What Was Tested

Researchers studied Buserelin in this randomized controlled trial publication.

A total of 312 patients with tubal infertility participated in a prospective randomized study comparing two regimens of ovarian stimulation with a luteinizing hormone-releasing hormone agonist (buserelin) and human menopausal gonadotrophin (HMG).

Who Took Part

The abstract describes 312 patients taking part.

By PubMed's age tags, the people studied were adults, women only.

Half of the patients were given an ultra-short treatment protocol when the agonist was administered on days 2, 3 and 4 of the stimulated cycles; the other half were given a long protocol when the agonist was administered from the mid-luteal phase of the cycle preceding the treatment cycle.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Buserelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

Topics PubMed links to this paper include Buserelin, Clinical Protocols, Down-Regulation, Fertilization in Vitro, Luteal Phase, Menotropins and Ovulation Induction.

What This Means in Plain Language

The paper is a randomized study of Buserelin in 312 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 1993 (Human reproduction (Oxford, England)), a journal based in England.

More context: all human trials.